Commit Biologics Closes $60 Million Seed Round

The financing will fund IND-enabling work and an IND filing for its COM002 development candidate.

Updated on Nov. 17, 2026 in Biotech

Isometric editorial illustration of a row of plain glass vials in a tray above a simple metal rack, rendered in muted oxblood, cream, and slate blue.
Copenhagen-based Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to fund its COM002 candidate toward an IND filing. AI Illustration. Upload story photo >

Commit Biologics completed a $60 million (€54 million) seed financing round, with the final close led by Ackermans & van Haaren. AbbVie Ventures and M Ventures joined as new investors alongside existing backers Bioqube Ventures, Korys and Novo Holdings.

Why it matters

The round gives the Copenhagen-based company capital to advance a second program into IND-enabling development, moving its bispecific complement engager platform closer to clinical testing. Its investor group includes large pharmaceutical and industrial backers, which signals interest in the platform's approach to immune cell depletion.

The announced figure is a $60 million (€54 million) seed round, and the source gives no comparison to other biotech seed rounds or prior company funding. The company has not disclosed the valuation or the expected timing of the COM002 IND filing.

The players

Commit Biologics

Commit Biologics is a biotechnology company headquartered in Copenhagen, Denmark, with a second base in Aarhus, that develops bispecific complement engager antibodies.

AbbVie Ventures

AbbVie Ventures is the venture investment arm of the global biopharmaceutical company AbbVie, which invests in early-stage life sciences companies.

Ackermans & van Haaren

Ackermans & van Haaren is a Belgian holding company with diversified investments across sectors, including a long-standing interest in healthcare and life sciences.

Novo Holdings

Novo Holdings is the Danish investment company that manages the foundation-owned assets of Novo Nordisk and invests in life sciences companies.

The details

The BiCE™ platform converts IgG antibodies into complement-powered immune engagers that recruit the complement protein C1q to eliminate targeted diseased cells through a T cell-independent mechanism. COM002, a dual-targeting molecule on this platform, was developed for cancer and autoimmune disease and was announced the week before the financing close.

Timeline

  1. Last week: COM002 development candidate announced.

  2. November 17, 2026: Seed financing final close announced.

Big Picture

The BiCE™ platform extends the complement-dependent cytotoxicity approach used by therapeutic antibodies such as rituximab, redirecting it toward targeted immune cell depletion through a T cell-independent route. Its seed round places it among a growing set of companies testing whether complement recruitment can complement existing T cell-based immunotherapies.

For most readers, this round changes nothing immediately, since COM002 has not yet entered clinical testing. Patients with cancer or autoimmune disease would only see access to a candidate if it advances through IND filing and clinical trials.

The takeaway

A seed round funding IND-enabling work marks an early stage in the path from preclinical research to patient treatment, so progress will be measured by future filings and trial results rather than by financing alone.

What happens next

The financing will support IND-enabling activities and an IND filing for COM002, with no specific dates provided in the source.

Further reading

Explore more coverage of Biotech developments and funding rounds.